2016
DOI: 10.1128/microbiolspec.tbtb2-0023-2016
|View full text |Cite
|
Sign up to set email alerts
|

Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays

Abstract: The identification of individuals with latent tuberculosis infection (LTBI) is useful for both fundamental understanding of the pathogenesis of disease and for clinical and public health interventions (i.e., to prevent progression to disease). Basic research suggests there is a pathogenetic continuum from exposure to infection to disease, and individuals may advance or reverse positions within the spectrum, depending on changes in the host immunity. Unfortunately, there is no diagnostic test that resolves the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
67
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 90 publications
(70 citation statements)
references
References 39 publications
2
67
0
1
Order By: Relevance
“…As a consequence, a large number of people need to be screened and treated to prevent one case of active TB [ 6 ]. Operational issues related to TST and IGRA may decrease screening uptake: The TST requires a second visit 48–72 h after the first visit to read the skin test induration (test result) and IGRA testing is generally costlier than TST and may not be as widely available in EU/EEA countries [ 61 ]. Patients with latent TB are asymptomatic and thus long treatment regimens ranging from 3 to 9 months lead to poor treatment completion [ 32 ].…”
Section: Discussionmentioning
confidence: 99%
“…As a consequence, a large number of people need to be screened and treated to prevent one case of active TB [ 6 ]. Operational issues related to TST and IGRA may decrease screening uptake: The TST requires a second visit 48–72 h after the first visit to read the skin test induration (test result) and IGRA testing is generally costlier than TST and may not be as widely available in EU/EEA countries [ 61 ]. Patients with latent TB are asymptomatic and thus long treatment regimens ranging from 3 to 9 months lead to poor treatment completion [ 32 ].…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, the IGRA sensitivity is not compromised by diabetes in TB patients; in fact, the sensitivity of QTF was significantly higher in TB patients with diabetes in comparison to those with no diabetes (41). The technical variations that may affect IGRA results include those related to blood sampling (time, volume), tube shaking, incubation or processing delay (cell viability in blood may be affected), incubation duration, analytical errors, and manufacturing defects (5).…”
Section: Diagnosis Of Ltbimentioning
confidence: 99%
“…The identification of individuals in contact with active TB cases during the first 2 years of exposure is important for two reasons: first, because it allows the implementation of public health policies of disease control by identifying individuals with an increased risk of developing the active tuberculosis; in particular, those who acquired the infection recently (4,5); and second, because it can lead to a better understanding of the immune response during infection, which could be instrumental in the development of better therapeutic and prophylactic interventions.…”
Section: Introductionmentioning
confidence: 99%
“…Retreatment with biological therapy should be considered case by case [17]. On the basis of clinical judgment, IGRA test (Interferon-Gamma Release Assay) could be performed every 12 months, and in case of positive results during treatment with tumor necrosis factor α (TNF-α), interleukins (IL)-12/23 or IL-17 blockers, it is necessary to consult an infectious diseases physician [18,19].…”
Section: Monitoring Of Patients During Treatment With Biological Agentsmentioning
confidence: 99%